ep beat sale estim consensu aid lower tax rate
ep guidanc rais beat pricing/competit concern diabet
trulic immunolog taltz appear short-liv stock may languish top line
visibl improv solid line new product pipelin depth support posit
outlook stock
ep estim consensu ep guidanc
increas vs prior last publish ep estim
review
sale estim
consensu drug beat estim includ humalog cyramza
ciali olumi zyprexa cymbalta verzenio tradjenta
combin forecast product forecast includ trulic
dampen greater mix higher discount busi price futur price
estim alimta taltz discount sale basaglar
strattera jardianc combin light
gpm estim
estim sg higher forecast net non-
oper expens estim pre-tax margin
estim tax rate estim ad
ep share count forecast
sale guidanc unchang last publish estim
net income/ expens guidanc updat prior
zero vs estim tax rate guidanc lower
vs prior vs estim line item guidanc unchang
manag also reiter oper margin target
selpercatinib file ret nsclc thyroid cancer tirzepatid initi
phase obes trulic file altern dose complet list event
shown follow page
pleas see page report import disclosur
cowen compani
good mm cowen
cowen compani www lilli com
cowen compani
cowen compani
cowen compani
cowen compani
time frameev chf exercis abil studiestirzepatid phase obes phase ii data lymphomaregulatoryjardiancefda adcom use insulin adjunct file ret nsclc thyroid cancertrulicityregulatori file altern dosesverzeni file label updat includ os data hr bccn file bc monarch plu corporatealimta patentgerman/japan appeal rule late erlotinibu /eu approv egfr nsclc pamphas ii data parkinson ii data mild alzheim solumiantphas data atop dermat two breez trial pegilodecakinphas ii data nsclc cypress data earli phase nsclc selpercatinib ph trial ret lung/thyroid cancerstaltzful ixora-r wk data wk data psoriasi vs tremfya posit top-lin aug phase data nr axspa posit top-lin apr penu approv approv episod cluster headachejardianceu approv insulin adjunct xr fdcu approv file pediatr sever plaqu psoriasistrulicityu approv rewind cv dataultra-rapid insulinu /eu approv file dose oa paintaltzu file non-radiograph ax spa cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl diabet portfolio
success pipelin product especi ramucirumab dulaglutid success
deal patent litig patent expir pressur uncertainti strateg
direct could includ outlook dividend greater expect
competit diabet affect franchis macro factor lessen appeal
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock secur
cowen compani llc act underwrit announc initi public offer elanco anim health incorpor subsidiari co
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
